Aggressive statin therapy for acute coronary syndromes.
Acute coronary syndromes (ACS) account for an enormous disease burden, especially in the Western world. Patients suffering acute coronary events are now understood to carry a very high risk of further coronary events and although improvements in conventional medical therapy over the past two decades have significantly reduced the risk, it remains high. Therapy with HMG CoA reductase inhibitors (statins) have now been well established for the primary and secondary prevention of stable coronary heart disease, but recently a substantial body of evidence has proven their efficacy in the treatment of ACS. This article examines this emerging evidence for the use of statins in ACS.
Vun Liew
Tze
T
Department of Public Health and Primary Care, Strangeways Research Laboratory, University of Cambridge, Cambridge CB1 8RN, UK.
Ray
Kausik K
KK
D000789:Angina, Unstable / Q000188:drug therapy* / Q000517:prevention & control; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000517:prevention & control; D016896:Treatment Outcome
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors